Evexia Diagnostics Partners with Genomind to Offer Cutting-Edge Pharmacogenetic Testing to Clinicians
Genomind’s new partnership with Evexia Diagnostics expands access to its pharmacogenetic testing, helping more clinicians personalize treatments and improve patient outcomes through genetic insights.
Genomind Launches First-of-Its-Kind Patient Report: Offering Patients an Easy-to-Understand View into Personalized Genetic Test Results
KING OF PRUSSIA, Pa.–(BUSINESSWIRE)–Genomind, a leader in medication management and personalized medicine through pharmacogenetics (PGx), is proud to announce the release of its innovative Patient Report. This new report empowers patients with easy-to-understand insights about how their genetics influence their body’s response to many medications. By making this information more accessible, the report fosters better […]
Genomind is Advancing how Healthcare Providers Prescribe Medications Better, Faster – Expanding Beyond Mental Health
Genomind is expanding its genetic panel and introducing a new streamlined report with actionable insights for patients – the Express Report
Shore Quality Partners Teams with Genomind to Help Prevent Adverse Prescription Drug Events
Integrated precision medication management platform empowers clinicians with genetic insights intended to reduce polypharmacy errors that cost thousands of lives and billions of dollars annually.
Genomind Pharmacogenetic Population Health Tool Highlighted in American Journal of Managed Care and 22nd Population Health Colloquium
Innovative approach addresses a huge and costly public health burden.
Genomind Completes Integration with Epic with support from Parkview Physicians Group
Parkview providers now able to order Genomind testing and view results within their Epic EHR system.
Cosán and Genomind Partner to Help Prevent Adverse Prescription Drug Events for Older Adults
Integrated precision medication management platform empowers clinicians with genetic insights intended to reduce polypharmacy errors that cost thousands of lives and billions of dollars annually.
David Nash MD to Join Genomind’s Scientific Advisory Board
Genomind®, a leading precision healthcare company named David Nash, MD, MBA of Jefferson Health the newest member of its Scientific Advisory Board (SAB).
Harmony United Psychiatric Care Enhances Behavioral Health Services with Genomind’s Precision Digital Mental Health Platform
Leading behavioral health practice Harmony United Psychiatric Care has integrated Genomind’s pharmacogenomic testing and services into Mendent EMR system.
CEO Shawn O’Brien Interviewed on WHBQ56 Sports Radio
Shawn O’Brien joined Johnny’s Radio Happy Hour on Sports 56 to explain Mental Health Map, partnering with Kevin Love & why parents should care about their child’s genetics.
CEO Shawn O’Brien Interviewed on KAHI Radio
Genomind CEO Shawn Patrick O’Brien joins Casey Freelove of KAHI Radio in Sacramento/ Auburn, CA to discuss Genomind’s tests, mission and initiatives.
Kevin Love & Genomind Join Forces to Introduce a New Expert Starting Point for Mental Wellness
Kevin Love partners with Genomind to introduce Mental Health Map, a genetic test designed to help people start their mental health and wellness journey.
Genomind Announces Two Major Appointments
Cynthia Kilroy Named Chief Strategy & Corporate Development Officer and Stephen R Saklad, PharmD, BCCP Joins the Company’s Scientific Advisory Board.
Pharmacogenetics Predictors of Methylphenidate Efficacy in Childhood ADHD
Review pharmacodynamic literature in an effort to identify clinically significant predictors of methylphenidate (MPH) response in children.
Genomind Launches GenMed Pro™ Precision Gene-Drug Interaction Software to Revolutionize the Prescription Process
Genomind®, the leader in comprehensive genetics and digital mental health services, has announced the launch of GenMed✔ Pro™ – Precision Gene-Drug Interaction Software.
Major Advancement in Support for Mental Health Patients as Medicare Provides Coverage of the Genomind Professional PGx Express Test and the VA Extends FSS Contract to Help Soldiers and Veterans
The Genomind pharmacogenetic test will be covered and reimbursed by Medicare. The VA has also elected to extend the current FSS contract for Genomind PGx.
Genomind and Stop Soldier Suicide Partner in Mission to Reduce Soldier and Veteran Suicides
Genomind and Stop Soldier Suicide Partner in Mission to Reduce Soldier and Veteran Suicides
Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for Tens of Thousands of Clinicians and Patients
Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test.
Genomind Releases Mental Health Map Consumer DNA Test
A breakthrough in the translation of genetic mechanisms and traits that can influence a person’s behavioral predispositions
Genomind Coordinates With Multiple Health Plans to Expand Access to Its Pharmacogenetics Tools and Help Reduce Mental Health-Related ER and Hospital Visits During the COVID-19 Crisis
Genomind Coordinates With Multiple Health Plans to Expand Access to Its Pharmacogenetics Tools and Help Reduce Mental Health-Related ER and Hospital Visits During the COVID-19 Crisis
Genomind Launches Express Ship-to-Patient Capability for Genomind Professional PGx Express Test Enabling Access to Critical Mental Health Treatment Information
Genomind becomes the first company to offer direct-to-patient, at-home mental health pharmacogenetic testing.
Genomind Substantially Increases Customer Access to Pharmacogenetic Mental Health Testing Through Expanded Partnership With Jewel-Osco
To help address the burgeoning mental health crisis in the U.S., specially trained Jewel-Osco pharmacists will play a pivotal role in expanding access to innovative mental health resources. This latest agreement quadruples number of pharmacies in Albertsons Companies offering Genomind’s tests and services.
Genomind Expands Collaboration to Provide Access to Genetics-Based Mental Health Test to Customers in All Pennsylvania ACME Markets
Partnering ACME pharmacists will identify and work with patients who may benefit from genetic testing service aimed at improving mental health treatments.
Genomind Joins Forces With Sharecare to Improve Mental Health Outcomes
Genomind brings expertise in mental health education and pharmacogenomics services to Sharecare’s comprehensive digital health platform.
Genomind Bolsters Medicare Reimbursement Initiatives, Obtaining Z-Codes for Genomind Professional PGx Express
Genomind announced the assignment of a Z-code for its mental health pharmacogenomic (PGx) testing.
Genomind Supports New Reimbursement Initiatives and Patient Access to Mental Health Pharmacogenomic Tests with PGx Report Focused on Anxiety and Depression
New CORE Depression and Anxiety Report follows UnitedHealthcare’s positive coverage decision for Genomind Professional PGx Express for certain patients.
Genomind and DrChrono Expand Collaboration to Improve Mental Health Outcomes With Innovative Technology and Services
Genomind and DrChrono Expand Collaboration to Improve Mental Health Outcomes With Innovative Technology and Services.
Researchers Present New Data on the Utility of Genomind’s Mental Health Pharmacogenomic Testing at Upcoming Scientific Conferences
Researchers Present New Data on the Utility of Genomind’s Mental Health Pharmacogenomic Testing at Upcoming Scientific Conferences.
Genomind Partners with NeuroFlow, Transforming Model of Care for Mental Health Patients
Genomind Partners with NeuroFlow, Transforming Model of Care for Mental Health Patients.
Genomind Expands Mental Health Genetic Testing Services with New Genomind Professional PGx Express
Genomind launches Genomind Professional PGx Express™, a new, more focused report and set of services to enhance its mental health genetic testing.
